WHO Launches EIOS 2.0 to Strengthen Global Health Intelligence and Threat Detection The World Health Organization (WHO) today announced the official launch of version 2.0 of its Epidemic Intelligence from Open Sources (EIOS) system, a major milestone in global health…
AbbVie to Present Comprehensive Data on Antibody-Drug Conjugate Portfolio at ESMO 2025, Reinforcing Leadership in Targeted Solid Tumor Therapies AbbVie (NYSE: ABBV) announced today that it will present a robust set of new clinical data from its antibody-drug conjugate (ADC)…
WuXi Biologics Applauds Sonoma Biotherapeutics Co-Founder Dr. Fred Ramsdell on Receiving the 2025 Nobel Prize in Physiology or Medicine WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), proudly congratulated Fred Ramsdell, PhD, co-founder and Chair…
Neurology Publication Demonstrates 95% Reduction in Mortality Risk with Pyrimidine Nucleos(t)ide Therapy in Patients with Thymidine Kinase 2 Deficiency (TK2d) UCB, a global biopharmaceutical company focused on the discovery and development of innovative treatments for serious diseases, today announced the…
BeOne Medicines’ Sonrotoclax Granted Breakthrough Therapy Designation by U.S. FDA, Set to Participate in Project Orbis BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology-focused biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA)…
LEQEMBI® IQLIK™ Subcutaneous Autoinjector Named One of TIME’s “Best Inventions of 2025” Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito) and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher) today announced that LEQEMBI® IQLIK™, a subcutaneous autoinjector…
Regeneron Presents Latest DB-OTO Data Showing Dramatic and Sustained Hearing and Speech Improvements in Children with Profound Genetic Hearing Loss Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced updated data for its investigational gene therapy DB-OTO for profound genetic hearing loss…
CVS Health® 2025 Rx Report Highlights the Evolution of Community Pharmacy to Meet Patient Needs CVS Health® (NYSE: CVS) today unveiled its 2025 Rx Report, Community Pharmacy Reimagined, offering a detailed exploration of how community pharmacies are evolving to meet…
AstraZeneca Showcases Transformative Oncology Pipeline with Breakthrough Data Across Multiple Cancer Types at ESMO 2025 AstraZeneca has reaffirmed its leadership in oncology innovation at the upcoming European Society for Medical Oncology (ESMO) Congress 2025, set to take place from October…
FDA Approves Updated Indication for AbbVie’s RINVOQ® (upadacitinib) Expanding Access for Patients with Inflammatory Bowel Disease AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) updating the indication…
Innate Pharma to Host Analyst and Investor Event Highlighting Lacutamab Clinical Data and Market Potential on October 28, 2025 Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA), a clinical-stage biopharmaceutical company focused on innovative immuno-oncology therapies, announced today that it…
BeOne Medicines Earns FDA Breakthrough Therapy Designation for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma, Strengthening Its Global Oncology Leadership BeOne Medicines Ltd., a leading global oncology-focused biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has…